Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ocular Therapeutix (OCUL) Accumulated Expenses: 2013-2025

Historic Accumulated Expenses for Ocular Therapeutix (OCUL) over the last 12 years, with Sep 2025 value amounting to $40.3 million.

  • Ocular Therapeutix's Accumulated Expenses rose 32.25% to $40.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $40.3 million, marking a year-over-year increase of 32.25%. This contributed to the annual value of $35.1 million for FY2024, which is 22.50% up from last year.
  • According to the latest figures from Q3 2025, Ocular Therapeutix's Accumulated Expenses is $40.3 million, which was up 17.01% from $34.4 million recorded in Q2 2025.
  • In the past 5 years, Ocular Therapeutix's Accumulated Expenses registered a high of $40.3 million during Q3 2025, and its lowest value of $13.6 million during Q1 2021.
  • In the last 3 years, Ocular Therapeutix's Accumulated Expenses had a median value of $28.9 million in 2023 and averaged $28.7 million.
  • Its Accumulated Expenses has fluctuated over the past 5 years, first surged by 180.50% in 2021, then decreased by 27.07% in 2024.
  • Ocular Therapeutix's Accumulated Expenses (Quarterly) stood at $20.1 million in 2021, then climbed by 19.76% to $24.1 million in 2022, then rose by 18.96% to $28.7 million in 2023, then rose by 22.50% to $35.1 million in 2024, then surged by 32.25% to $40.3 million in 2025.
  • Its Accumulated Expenses stands at $40.3 million for Q3 2025, versus $34.4 million for Q2 2025 and $31.1 million for Q1 2025.